Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer

Macro Bregni, K. Fleischhauer, M. Bernardi, A. Pescarollo, E. Guggiari, F. Lunghi, Sara Deola, S. Scaramuzza, F. Re, E. Setola, M. Monari, B. Mazzi, P. Servida, P. Corradini, J. Peccatori

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We assessed mammaglobin (MMG) gene expression in bone marrow (BM) aspirates from patients with advanced breast cancer who had received a reduced-intensity conditioning and stem cell allografting, in order to detect a graft-versus-tumor effect on micrometastatic disease. Nine patients received a reduced-intensity conditioning with fludarabine, cyclophosphamide, and thiotepa, followed by peripheral blood allografting from HLA-identical sibling donors. Nested RT-PCR analysis with sequence-specific primers for MMG was carried out on a monthly basis on BM samples. Three patients had MMG-positive BM, four patients had MMG-negative BM before allografting, and two were undetermined. In two patients, a clinical response after allografting (partial remission) occurred concurrently with the clearance of MMG expression, at a median of 6 months after allografting, following immune manipulation. In two patients, a prolonged stable disease and negative MMG expression occurred after day +360 from allografting. In two patients, progression of the disease was associated with MMG RT-PCR changing from negative to positive. In one case, a disease response occurring after donor lymphocyte infusion and grade II acute GVHD was heralded by negativization of MMG expression. Although preliminary, these data suggest that a graft-versus-breast cancer effect is detectable on micrometastatic BM disease.

Original languageEnglish
Pages (from-to)311-315
Number of pages5
JournalBone Marrow Transplantation
Volume37
Issue number3
DOIs
Publication statusPublished - 1 Feb 2006
Externally publishedYes

Fingerprint

Homologous Transplantation
Bone Marrow
Breast Neoplasms
Transplants
Neoplasms
Bone Marrow Diseases
Tissue Donors
Thiotepa
Polymerase Chain Reaction
Cyclophosphamide
Sequence Analysis
Disease Progression
Siblings
Stem Cells
Lymphocytes
Gene Expression

Keywords

  • Allogeneic bone marrow transplantation
  • Breast cancer
  • Mammaglobin

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer. / Bregni, Macro; Fleischhauer, K.; Bernardi, M.; Pescarollo, A.; Guggiari, E.; Lunghi, F.; Deola, Sara; Scaramuzza, S.; Re, F.; Setola, E.; Monari, M.; Mazzi, B.; Servida, P.; Corradini, P.; Peccatori, J.

In: Bone Marrow Transplantation, Vol. 37, No. 3, 01.02.2006, p. 311-315.

Research output: Contribution to journalArticle

Bregni, M, Fleischhauer, K, Bernardi, M, Pescarollo, A, Guggiari, E, Lunghi, F, Deola, S, Scaramuzza, S, Re, F, Setola, E, Monari, M, Mazzi, B, Servida, P, Corradini, P & Peccatori, J 2006, 'Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer', Bone Marrow Transplantation, vol. 37, no. 3, pp. 311-315. https://doi.org/10.1038/sj.bmt.1705248
Bregni, Macro ; Fleischhauer, K. ; Bernardi, M. ; Pescarollo, A. ; Guggiari, E. ; Lunghi, F. ; Deola, Sara ; Scaramuzza, S. ; Re, F. ; Setola, E. ; Monari, M. ; Mazzi, B. ; Servida, P. ; Corradini, P. ; Peccatori, J. / Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer. In: Bone Marrow Transplantation. 2006 ; Vol. 37, No. 3. pp. 311-315.
@article{b1562167ba3b48ed8123a15d3e1265db,
title = "Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer",
abstract = "We assessed mammaglobin (MMG) gene expression in bone marrow (BM) aspirates from patients with advanced breast cancer who had received a reduced-intensity conditioning and stem cell allografting, in order to detect a graft-versus-tumor effect on micrometastatic disease. Nine patients received a reduced-intensity conditioning with fludarabine, cyclophosphamide, and thiotepa, followed by peripheral blood allografting from HLA-identical sibling donors. Nested RT-PCR analysis with sequence-specific primers for MMG was carried out on a monthly basis on BM samples. Three patients had MMG-positive BM, four patients had MMG-negative BM before allografting, and two were undetermined. In two patients, a clinical response after allografting (partial remission) occurred concurrently with the clearance of MMG expression, at a median of 6 months after allografting, following immune manipulation. In two patients, a prolonged stable disease and negative MMG expression occurred after day +360 from allografting. In two patients, progression of the disease was associated with MMG RT-PCR changing from negative to positive. In one case, a disease response occurring after donor lymphocyte infusion and grade II acute GVHD was heralded by negativization of MMG expression. Although preliminary, these data suggest that a graft-versus-breast cancer effect is detectable on micrometastatic BM disease.",
keywords = "Allogeneic bone marrow transplantation, Breast cancer, Mammaglobin",
author = "Macro Bregni and K. Fleischhauer and M. Bernardi and A. Pescarollo and E. Guggiari and F. Lunghi and Sara Deola and S. Scaramuzza and F. Re and E. Setola and M. Monari and B. Mazzi and P. Servida and P. Corradini and J. Peccatori",
year = "2006",
month = "2",
day = "1",
doi = "10.1038/sj.bmt.1705248",
language = "English",
volume = "37",
pages = "311--315",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer

AU - Bregni, Macro

AU - Fleischhauer, K.

AU - Bernardi, M.

AU - Pescarollo, A.

AU - Guggiari, E.

AU - Lunghi, F.

AU - Deola, Sara

AU - Scaramuzza, S.

AU - Re, F.

AU - Setola, E.

AU - Monari, M.

AU - Mazzi, B.

AU - Servida, P.

AU - Corradini, P.

AU - Peccatori, J.

PY - 2006/2/1

Y1 - 2006/2/1

N2 - We assessed mammaglobin (MMG) gene expression in bone marrow (BM) aspirates from patients with advanced breast cancer who had received a reduced-intensity conditioning and stem cell allografting, in order to detect a graft-versus-tumor effect on micrometastatic disease. Nine patients received a reduced-intensity conditioning with fludarabine, cyclophosphamide, and thiotepa, followed by peripheral blood allografting from HLA-identical sibling donors. Nested RT-PCR analysis with sequence-specific primers for MMG was carried out on a monthly basis on BM samples. Three patients had MMG-positive BM, four patients had MMG-negative BM before allografting, and two were undetermined. In two patients, a clinical response after allografting (partial remission) occurred concurrently with the clearance of MMG expression, at a median of 6 months after allografting, following immune manipulation. In two patients, a prolonged stable disease and negative MMG expression occurred after day +360 from allografting. In two patients, progression of the disease was associated with MMG RT-PCR changing from negative to positive. In one case, a disease response occurring after donor lymphocyte infusion and grade II acute GVHD was heralded by negativization of MMG expression. Although preliminary, these data suggest that a graft-versus-breast cancer effect is detectable on micrometastatic BM disease.

AB - We assessed mammaglobin (MMG) gene expression in bone marrow (BM) aspirates from patients with advanced breast cancer who had received a reduced-intensity conditioning and stem cell allografting, in order to detect a graft-versus-tumor effect on micrometastatic disease. Nine patients received a reduced-intensity conditioning with fludarabine, cyclophosphamide, and thiotepa, followed by peripheral blood allografting from HLA-identical sibling donors. Nested RT-PCR analysis with sequence-specific primers for MMG was carried out on a monthly basis on BM samples. Three patients had MMG-positive BM, four patients had MMG-negative BM before allografting, and two were undetermined. In two patients, a clinical response after allografting (partial remission) occurred concurrently with the clearance of MMG expression, at a median of 6 months after allografting, following immune manipulation. In two patients, a prolonged stable disease and negative MMG expression occurred after day +360 from allografting. In two patients, progression of the disease was associated with MMG RT-PCR changing from negative to positive. In one case, a disease response occurring after donor lymphocyte infusion and grade II acute GVHD was heralded by negativization of MMG expression. Although preliminary, these data suggest that a graft-versus-breast cancer effect is detectable on micrometastatic BM disease.

KW - Allogeneic bone marrow transplantation

KW - Breast cancer

KW - Mammaglobin

UR - http://www.scopus.com/inward/record.url?scp=33645320590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645320590&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705248

DO - 10.1038/sj.bmt.1705248

M3 - Article

VL - 37

SP - 311

EP - 315

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -